Becky Hollenberg

speaker

57 appearances 1 recordings 1 series first heard Jul 2026 last heard 13 Jul

Becky Hollenberg’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

tHEORetically Speaking · From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap · 13 Jul 2026 podcast

And then the payer and policy data is going to understand what access barriers are shaping care and how do those play into those treatment decisions and the rationale that the physician is making.

Individually, there are partial data sources, but the value comes from connecting them into one clinical record that has all the

clinical lab and narrative access signals for one patient all combined.

So that's going to lead to more accurate cohort definitions, better confounder adjustment, stronger outcomes capture, clearer access and barrier identification, and a more defensible value story because you're seeing more of the picture and more of the holistic patient journey.

So if we look across a patient journey, for example, ICD-10 plus labs could show the confirmed diagnosis based on phenotypes and ICD-10 code.

Notes will kind of unlock why a treatment was chosen or why a switch happened, whether it was an efficacy signal, a tolerability signal, right?

access problem.

And then claims, we can then track how that switch occurred.

Did the patient get on therapy?

And then using labs and progress notes, we can see the outcomes of that and how did the patient respond to their treatment switch.

Yeah, so for market access teams, it's going to be focused on defending access against payer restrictions.

So that could be quantifying the impact of payer restrictions, identifying the unmet need populations, understanding drivers of abandonment, building a payer dossier.

grounded in clinical reality and informing contracting and access strategy.

On the HUR side, it's going to mean sharper evidence that's more defensible to scrutiny from external stakeholders.

So that could mean improved cohort definitions and identification, reducing misclassification bias, adjusting for disease severity within our cohort definitions, linking to real-world outcomes and access pathways,

more comparative effectiveness studies that are stronger with their evidence and overall more credible economic evidence.

From a medical affairs side, it's kind of combining the clinical and the access story.

So understanding treatment rationale and unmet need, identifying if there are any gaps between guidelines and how physicians are actually practicing, characterizing disease burden, and informing evidence generation priorities so that they can equip their MSL teams to be able to speak to that.

So the unifying point here is that all three work off of one unified value story.

So with the same underlying data, even though the actions based on those takeaways might be different, the takeaways individually should be the same and kind of create that unified story.

Showing 21–40 of 57 · page 2 of 3